# Starling Oncology, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Starling Oncology, Inc.).

## Overview

Starling Oncology, Inc. manages community-based oncology practices through affiliated physician-owned professional corporations and contracted provider networks in the United States. Its care platform combines medical and radiation oncology, infusion services, specialty pharmacy, clinical trials, and value-based arrangements with payors and other risk-bearing entities.

## Products & services

• Medical and radiation oncology services
• In-house infusion and chemotherapy care
• Specialty pharmacy and oral oncology drugs
• Clinical trials and research services
• Value-based oncology care management
• Patient support, counseling, and palliative care

- **Patient Services** (55%) — Physician oncology, hematology, radiation, infusion, and supportive care delivered through community clinics.
- **Value-Based Care Management** (20%) — Population-level oncology management under capitation, gain/loss sharing, and delegated contracts.
- **Specialty Pharmacy** (15%) — Oral oncology prescriptions dispensed through affiliated practice dispensaries to insured patients.
- **Clinical Trials and Research** (7%) — Clinical research administration, patient visits, and trial-related services for sponsors.
- **Other Support Services** (3%) — Patient education, counseling, support groups, care coordination, and related services.

- Medical and radiation oncology services
- In-house infusion and chemotherapy care
- Specialty pharmacy and oral oncology drugs
- Clinical trials and research services
- Value-based oncology care management
- Patient support, counseling, and palliative care

## Customers

Starling primarily serves patients receiving cancer treatment through community-based oncology practices, where convenience, coordinated care, and access to subspecialized services are important. Payors, employers, managed care organizations, and other risk-bearing entities contract with Starling to manage oncology populations and pursue lower-cost, evidence-based treatment pathways. Pharmaceutical and biotechnology companies engage affiliated practices for clinical trial services, while PBMs and third-party payors reimburse specialty pharmacy prescriptions.

- **Cancer Patients** (primary) — Receive oncology, infusion, radiation, pharmacy, counseling, and supportive care in community settings.
- **Health Plans and Risk-Bearing Payors** (primary) — Purchase delegated, capitated, and shared-risk oncology management to control treatment costs and coordinate care.
- **Employers and Managed Care Organizations** (secondary) — Use value-based oncology arrangements intended to improve outcomes and reduce avoidable treatment spending.
- **PBMs and Third-Party Pharmacy Payors** (secondary) — Set reimbursement schedules for oral oncology drugs dispensed through affiliated practice pharmacies.
- **Clinical Trial Sponsors** (emerging) — Engage affiliated practices for trial administration, patient visits, and research-related activities.

- Cancer patients seek local, coordinated oncology treatment
- Health plans contract for managed oncology populations
- Employers benefit from lower-cost cancer care pathways
- PBMs and payors reimburse oral oncology prescriptions
- Trial sponsors pay for clinical research services

## Geography

Starling operates across 17 markets and five U.S. states through 65 community-based oncology practices, affiliated professional corporations, and contracted provider networks. Its affiliated practices include operations in California, Florida, Oregon, and Texas, while the broader network includes 791 Florida providers and 11 unaffiliated California providers as of June 30, 2026. Geographic expansion relies on delegated contracts and existing provider infrastructure, while state corporate-practice-of-medicine rules influence the company’s physician-entity structure.

- **United States** (100%) — All disclosed operations are in the United States; no regional revenue percentages were provided.

- Operations span 17 markets across five U.S. states
- 65 affiliated community oncology practices
- Florida network includes 791 managed providers
- California network includes 11 independent providers
- State medical-practice laws shape affiliated entities

## Strategy

Starling’s strategy is to scale a vertically integrated, value-based oncology model through delegated payor contracts, affiliated clinics, and managed independent providers. The company also seeks to broaden clinical and ancillary services, use acquisitions to enter new markets, and strengthen adherence to clinical pathways through provider technology. This model is intended to give Starling greater influence over physician behavior and referrals than traditional fee-for-service practices or standalone specialty benefit managers.

- **Delegated contract expansion** (short-term) — Delegation gives Starling responsibility for coordinating oncology care and supports recurring population-based arrangements.
- **New-market development** (medium-term) — A repeatable operating model can leverage existing providers before selectively building affiliated clinics.
- **Practice acquisitions** (medium-term) — Acquisitions can expand geographic presence while bringing independent oncologists into Starling’s value-based platform.
- **Integrated service expansion** (medium-term) — Ancillary services increase patient access and deepen Starling’s role across the oncology care pathway.
- **Provider technology adoption** (short-term) — Digital tools are intended to improve provider engagement and compliance with evidence-based clinical pathways.

- Expand delegated and capitated oncology contracts
- Enter new markets through provider infrastructure
- Acquire aligned oncology practices
- Add pharmacy, trials, radiation, and palliative services
- Improve pathway adherence through provider technology
- Use integrated care to compete on cost and outcomes

## Risks

Starling’s growth depends on recruiting or acquiring clinics, securing payor contracts, and managing physician networks across state-specific regulatory structures. Its oncology model also depends on uninterrupted drug supply, reliable information systems, and accurate coordination of high-cost treatments. Regulatory changes, competitive pressure, weather disruptions, and adverse healthcare-industry publicity could reduce access to patients, increase compliance costs, or impair operating results.

- **Dependence on clinic growth and acquisitions** [high] — The expansion model requires enough affiliated practices and providers to service contracts and treat covered patients.
- **Payor and delegated-contract concentration** [high] — Loss, repricing, or underperformance of managed-care contracts could reduce covered lives and recurring care-management revenue.
- **Single-source oncology drug supply** [high] — A disruption, price increase, or logistics failure at the supplier could impair pharmacy and infusion services.
- **Information technology and cybersecurity failure** [high] — Clinical, billing, pharmacy, and provider-management workflows depend on company and third-party systems.
- **Healthcare regulatory change** [high] — Changes affecting managed care, physician ownership, reimbursement, or marketing could increase costs or restrict operations.
- **Clinic disruption from external events** [medium] — Hurricanes, floods, fires, disease outbreaks, violence, or other events can interrupt scheduling and temporarily close facilities.

- Clinic acquisition and recruitment are required for expansion
- Payor contract losses could reduce managed patient populations
- Single-source drug supply creates disruption and pricing exposure
- Cyberattacks could interrupt clinical and pharmacy operations
- State practice-of-medicine rules complicate entity structures
- Weather events can close clinics and disrupt care

## Accounting

Revenue recognition varies by service: fee-for-service patient revenue is generally recorded when care is delivered, while clinical trial revenue is recognized over time as contracted research activities and patient visits occur. Capitation, gain/loss sharing, and delegated arrangements require estimates of covered populations, medical costs, contractual settlements, and performance obligations, which can affect reported revenue and margins. Starling also consolidates affiliated professional corporations as variable interest entities and must account for operating leases, acquisition consideration, and its convertible note obligations.

- **Patient-service revenue recognition** — Timing and collectability affect reported revenue and receivables.
- **Value-based contract estimates** — Changes in medical-cost expectations can affect revenue, provisions, and operating results.
- **Clinical trial contract accounting** — Revenue timing depends on trial progress and completion of performance obligations.
- **Variable interest entity consolidation** — Consolidation brings the PCs' revenue, expenses, assets, and liabilities into reported results.
- **Lease and acquisition accounting** — Lease liabilities, amortization, goodwill, and contingent payments can affect reported earnings and cash flow.

- Fee-for-service revenue is recorded when patient services occur
- Clinical trial revenue is recognized over contract progress
- Capitation requires estimates of care obligations and settlements
- VIE consolidation includes affiliated physician corporations
- Drug costs and clinician costs affect patient-service margins
- Leases and convertible notes affect liabilities and cash needs

---

*Last updated: 2026-09-24T11:22:41.486738+00:00*